Opko Health, Inc. (NASDAQ:OPK) notched a -1.01% intraday decline moving at $4.9. When the opening bell rang, the price was $4.92. The number of shares that were traded during the day was 4.53 million, which corresponds to its 3-month volume average of 4.35 million shares a day.Opko Health, Inc. (OPK) Analyst Opinion
Opko Health, Inc. has a consensus outperform rating from 6 Wall Street analysts, and the number of shares currently sold short amount to at least 18.53% of shares outstanding. The stock sank -1.8% last month and is down -47.31 this year. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover OPK having a buy-equivalent rating. Analysts have placed a $12.75 price target on Opko Health, Inc., suggesting a 160.2% gain from recent close. It’s currently trading about -57.56% below its 52-week high.Opko Health, Inc. Earnings Surprise
Opko Health, Inc. (OPK) revenue totaled $319.43 million up 1.66% from the previous quarter.Opko Health, Inc. (NASDAQ:OPK) Intraday View
This stock (OPK) is ahead of its 52-week low with 8.89%. Its last month’s stock price volatility remained 2.83% which for the week stands at 3.41%. The share price has moved backward from its 20 days moving average, trading at a distance of -2.71% and stays -11.74% away from its 50 days moving average. Over the last five days, shares have faced -2.58% losses and now is down -24.36% since hitting its 200-day moving average of $6.12. Opko Health, Inc. (OPK) has made its way to a 12-month decline of -57.24%.
Turning to Five Prime Therapeutics, Inc. (NASDAQ:FPRX), its shares were trading at $21.92 a retreat of $-0.59, on the trading floor. The stock, after opening at $22.5, touched a high of $22.8 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.4. Five Prime Therapeutics, Inc. has 5 buy ratings, 0 holds and 0 sells even after the stock tumbled -58.63% from its high of $52.98 to a $640.72 million market value through last close.Five Prime Therapeutics, Inc. (FPRX) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.44 to 1.44 during a month. Analysts set a 12-month price target of $63.06 a share. The target implies a 187.68% spike from where the shares are currently trading. Also, the current price highlights a discount of 328.83% to analysts’ high consensus price target.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Intraday Trading
The counter witnessed a trading volume of 0.31 million shares versus an average volume of 0.65 million shares during last trading session. Its last month’s stock price volatility remained 4.61% which for the week approaches 5.85%. The lowest price the stock reached in the last trading day was $21.91 and compares with the $19.73 52-week low. The stock recovered 11.1% since its low point and has performed -56.26% year-to-date.